Vascular Closure Device Market, by Product Type (Passive Vascular Closure Devices, Active Vascular Closure Devices, and External Hemostatic Devices), By Access (Femoral, and Radial), By Hole Size (Small Hole, and Large Hole) By End User (Hospitals, Ambulatory Surgical Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Dec 2023

Code : CMI1330

Pages :233

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments:

New product launches & Approval:

On September 6, 2023, Boston Scientific Corporation, a medical device company, announced it had received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device.
In September 2022, Haemonetics Corporation, a global medical technology company, announced it had earned Conformité Européenne (CE) mark certification for its VASCADE vascular closure and VASCADE MVP venous vascular closure systems. The CE marking will allow Haemonetics to engage in the next steps of country-specific entrance of both products into the European Union (EU) and form the basis for entry into other geographies that recognize CE marking.
In May 2022, Teleflex Incorporated, a leading global provider of medical technologies, announced that it received Health Canada approval for the MANTA Vascular Closure Device, the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure. This approval provide opportunity in the regulatory plan to expand the availability of the MANTA Device globally and provides access to another uniquely designed device from Teleflex for Canadian clinicians.

Acquisition, Collaboration and partnerships:

On November 30, 2023, Johnson & Johnson Service Inc., a biotechnology company, announced the completion of the acquisition of Laminar, Inc., a privately held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).